Science Board to the Food and Drug Administration
via Videoconference
June 14, 2022

AGENDA

9:00 a.m. Opening Introductions
Barbara Kowalcyk, PhD, Science Board Chair

9:05 a.m. Conflict of Interest
Rakesh Raghuwanshi, MPH, Designated Federal Officer, Science Board, FDA

9:10 a.m. New Alternative Methods
Janet Woodcock, MD, Principal Deputy Commissioner, FDA
David Strauss, MD, PhD, Director, Division of Applied Regulatory Science, CDER
Jacqueline O’Shaughnessy, PhD, Acting Chief Scientist, FDA

10:10 a.m. Commissioner's Update and Data Science Efforts
Robert Califf, MD, Commissioner of Food and Drugs, FDA

11:00 a.m. Open Public Hearing

12:00 p.m. Break

12:30 p.m. CFSAN Session: Challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity
Janet Woodcock, MD, Principal Deputy Commissioner, FDA
Patrick Cournoyer, PhD, Acting Science and Policy Coordinator, Cannabis Product Committee, Office of the Commissioner
Cassandra Taylor, PhD, Chemist, Botanical Review Team, Office of Pharmaceutical Quality, CDER, FDA
Gregory Noonan, PhD, Acting Deputy Director, Office of Dietary Supplement Programs, CFSAN, FDA
Jeremy Gingrich, PhD, Toxicologist, Office of Food Additive Safety, CFSAN, FDA
Steven Musser, PhD, Deputy Director for Scientific Operations, CFSAN, FDA

4:30 p.m. Final Thoughts, and Closing Comments
Barbara Kowalcyk, PhD, Science Board Chair